Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Mesenchymal Stem Cells Attenuate Sepsis-associated Acute Kidney Injury by Changing the Balance of Th17 cells/Tregs via Gal-9/Tim-3

Author(s): Congjuan Luo, Feng Luo, Xiaofei Man, Xuemei liu, Long Zhao, Lin Che, Wei Zhang, Junjie Guo, Shixia Cai, Dawei Wang and Yan Xu*

Volume 18, Issue 4, 2023

Published on: 29 August, 2022

Page: [540 - 550] Pages: 11

DOI: 10.2174/1574888X17666220511151343

Price: $65

Abstract

Objective: The aim of the present study was to investigate the protective effect of MSCs on CLP-induced SA-AKI and determine the mechanisms of this effect.

Methods: The expression of Gal-9 and Tim-3 was assayed by qPCR and western blot. IL-10, IL-17, RORγt, and FOXP3 were assayed by qPCR and TNFα, INFγ, IL-4, and IL-6 were assayed by ELISA in renal samples after CLP with or without MSCs treatment. The expression of Gal-9 in MSCs was knocked down in vivo using RNA interference, and si-Gal-9-MSCs were injected in SA-AKI mice. The effect of MSCs on the differentiation of lymphocytes into Th17 cells and Tregs was evaluated in vitro by FAC in coculture of MSCs and CD4+ T cells and after blockade of the Gal-9/Tim-3 pathway.

Results: MSCs decreased serum creatinine and urea nitrogen levels and relieved tubular injury. Additionally, MSCs significantly improved the survival rate and markedly attenuated the infiltration of neutrophils and the levels of TNF-α, IFN-γ, IL-4, and IL-6 in the kidneys of septic mice (P < 0.05). Treatment with MSCs also reduced the proportion of Th17 cells and the levels of IL-17 and RORγt (P < 0.05). In contrast, MSCs increased the proportion of Tregs and the levels of IL-10 and FOXP3 related to these cells (P < 0.05). Furthermore, we determined whether Gal-9/Tim-3 and Th17 cells/Tregs are involved in the protective effects of MSCs in an SA-AKI model. The results of Western blot and real-time PCR indicated that MSCs inhibited the expression of Tim-3 and increased the expression of gal-9 (P < 0.05). Knockdown of gal-9 in MSCs using small interfering RNA blunted the therapeutic effect of MSCs, and blockade of the Gal-9/Tim-3 pathway using α-lactose or anti-Tim-3 inhibited the induction of Tregs and suppressed the inhibition of the differentiation to Th17 cells by MSCs after coculture of MSCs with CD4+ T cells (P > 0.05).

Conclusion: Treatment with MSCs can protect against SA-AKI. The results suggested that the relieving effect of MSCs against SA-AKI may be partially mediated by the induction of Tregs and inhibition of Th17 cells via the Gal-9/Tim-3 pathway.

Keywords: Mesenchymal stem cells, sepsis-associated acute kidney injury, Th17 /Tregs, Gal-9/Tim-3, attenuated, tubular injury.

« Previous Next »
[1]
Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294(7): 813-8.
[http://dx.doi.org/10.1001/jama.294.7.813] [PMID: 16106006]
[2]
Keir I, Kellum JA. Acute kidney injury in severe sepsis: Pathophysiology, diagnosis, and treatment recommendations. J Vet Emerg Crit Care (San Antonio) 2015; 25(2): 200-9.
[http://dx.doi.org/10.1111/vec.12297] [PMID: 25845505]
[3]
Joannidis M, Druml W, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: Update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med 2017; 43(6): 730-49.
[http://dx.doi.org/10.1007/s00134-017-4832-y] [PMID: 28577069]
[4]
Uhle F, Lichtenstern C, Brenner T, Weigand MA. Anasthesiol intensivmed notfallmed schmerzther. Pathophysiology of sepsis 2015; 50: 114-22.
[5]
Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014; 13: 668-77.
[6]
Lee GR. The Balance of Th17 versus Treg Cells in autoimmunity. Int J Mol Sci 2018; 19(3): 730.
[http://dx.doi.org/10.3390/ijms19030730] [PMID: 29510522]
[7]
Chen J, Zhang X, Xie J, et al. Overexpression of TGFβ1 in murine mesenchymal stem cells improves lung inflammation by impacting the Th17/Treg balance in LPS-induced ARDS mice. Stem Cell Res Ther 2020; 11(1): 311.
[http://dx.doi.org/10.1186/s13287-020-01826-0] [PMID: 32698911]
[8]
Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I. Friederike Gieseke 1, Anne Kruchen, Nikolay Tzaribachev, Frank Bentzien, Massimo Dominici, Ingo Müller. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur J Immunol 2013; 43(10): 2741-9.
[http://dx.doi.org/10.1002/eji.201343335]
[9]
Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif 2020; 53, e12712.
[10]
Sioud M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol 2011; 73(2): 79-84.
[http://dx.doi.org/10.1111/j.1365-3083.2010.02491.x] [PMID: 21198747]
[11]
Luo CJ, Zhang FJ, Zhang L, et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 2014; 41(2): 123-9.
[http://dx.doi.org/10.1097/SHK.0000000000000080] [PMID: 24169208]
[12]
Zhang Q, Luan H, Wang L, et al. Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice. Am J Physiol Renal Physiol 2014; 306(8): F822-32.
[http://dx.doi.org/10.1152/ajprenal.00294.2013] [PMID: 24477688]
[13]
Oomizu S, Arikawa T, Niki T, et al. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PLoS One 2012; 7(11), e48574.
[http://dx.doi.org/10.1371/journal.pone.0048574] [PMID: 23144904]
[14]
de Castro LL, Lopes-Pacheco M, Weiss DJ, Cruz FF, Rocco PRM. Current understanding of the immunosuppressive properties of mesenchymal stromal cells. J Mol Med (Berl) 2019; 97(5): 605-18.
[http://dx.doi.org/10.1007/s00109-019-01776-y] [PMID: 30903229]
[15]
Bernardo ME, Fibbe WE. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 2013; 13(4): 392-402.
[http://dx.doi.org/10.1016/j.stem.2013.09.006] [PMID: 24094322]
[16]
Ghannam S, Pène J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185(1): 302-12.
[http://dx.doi.org/10.4049/jimmunol.0902007] [PMID: 20511548]
[17]
Sávio-Silva C, Soinski-Sousa PE, Balby-Rocha MTA, Lira ÁO, Rangel ÉB. Mesenchymal stem cell therapy in acute kidney injury (AKI): Review and perspectives. Rev Assoc Med Bras 2020; 2020(66) (Suppl. 1): s45-54.
[http://dx.doi.org/10.1590/1806-9282.66.s1.45] [PMID: 31939535]
[18]
Andrade-Oliveira V, Foresto-Neto O, Watanabe IKM, Zatz R, Câmara NOS. Front Pharmacol. Inflammation in Renal Diseases: New and Old Players 2019; 10: 1192.
[19]
de Witte SF, Franquesa M, Baan CC, Hoogduijn MJ. Toward development of imesenchymal stem cells for immunomodulatory therapy. Front Immunol 2016; 6: 648.
[http://dx.doi.org/10.3389/fimmu.2015.00648] [PMID: 26779185]
[20]
Luz-Crawford P, Kurte M, Bravo-Alegría J, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 2013; 4(3): 65.
[http://dx.doi.org/10.1186/scrt216] [PMID: 23734780]
[21]
Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy 2016; 18(2): 160-71.
[http://dx.doi.org/10.1016/j.jcyt.2015.10.011] [PMID: 26794710]
[22]
Dings RPM, Miller MC, Griffin RJ, Mayo KH. Galectins as molecular targets for therapeutic intervention. Int J Mol Sci 2018; 19(3): 905.
[http://dx.doi.org/10.3390/ijms19030905] [PMID: 29562695]
[23]
Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol 2011; 38(2): 385-90.
[http://dx.doi.org/10.3892/ijo.2010.869] [PMID: 21165555]
[24]
Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol 2010; 71(4): 267-74.
[http://dx.doi.org/10.1111/j.1365-3083.2010.02378.x] [PMID: 20384870]
[25]
Toscano MA, Bianco GA, Ilarregui JM, et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007; 8(8): 825-34.
[http://dx.doi.org/10.1038/ni1482] [PMID: 17589510]
[26]
Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6(12): 1245-52.
[http://dx.doi.org/10.1038/ni1271] [PMID: 16286920]
[27]
Yang R, Sun L, Li CF, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 2021; 12(1): 832.
[http://dx.doi.org/10.1038/s41467-021-21099-2] [PMID: 33547304]

Rights & Permissions Print Cite
Article Metrics
17
© 2024 Bentham Science Publishers | Privacy Policy